Youngpoong Famciclovir Tablets 250 mg

Adult dosage

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer 250 mg of this drug orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer 125 mg of this drug orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal phase or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this drug orally 2 times daily. Periodically discontinue treatment every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the creatinine clearance of this drug is reduced in patients with renal impairment, dosage adjustments should be made with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose, 2 times daily 10～29: 250 mg per dose, once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose, 2 times daily 10～29: 125 mg per dose, once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose, 2 times daily 10～29: 125 mg per dose, 2 times daily 4) If only the serum creatinine level is known, creatinine clearance can be calculated using the following equations. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, it is preferable to administer this drug every 48 hours, taking the dialysis interval into account. Since 4 hours of hemodialysis reduces the plasma concentration of this drug by approximately 75%, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dosage adjustment is needed in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medicine should not be used in certain patients. It should not be administered to patients who have had allergic reactions to this medicine or its components. Additionally, this medicine contains lactose, and patients with genetic disorders that prevent lactose digestion should also refrain from taking it. Patients with kidney function problems should use this medicine cautiously, and dose adjustment may be necessary. While taking this medicine, symptoms such as headache, nausea, dizziness, and drowsiness may occur, and especially in the elderly, drowsiness or confusion may occur more frequently. Rarely, thrombocytopenia, palpitations, skin rashes, itching, and severe skin reactions have been reported. Serious side effects, such as liver dysfunction or acute renal failure, may also occur rarely, so it is important to periodically check liver and kidney function status. This medicine does not cure genital herpes, and it is recommended to avoid sexual contact if symptoms persist during treatment. Furthermore, guidance should be provided to maintain safe sexual practices and to initiate treatment immediately when recurrent symptoms appear. If dizziness, drowsiness, or confusion occurs while taking this medicine, avoid driving or operating machinery. Patients with slight liver damage do not require special dose adjustments, however, in patients with severe liver impairment, efficacy may decline, so caution is necessary. This medicine has minimal interaction with most drugs, but caution should be taken as blood concentrations may change when combined with certain medications. In particular, there is a risk of toxicity when combined with probenecid, so dose adjustment may be necessary under a doctor's guidance. Women who are pregnant or of childbearing potential should carefully consider the benefits and risks of taking this medicine, as should breastfeeding women. It is preferable not to use this medicine in children under 18 years of age, as safety and efficacy have not been established. In general, elderly patients do not need dose adjustments, but in cases of reduced kidney function, dosage should be adjusted. In case of overdose, appropriate treatment should be received, and hemodialysis may reduce the concentration of the active ingredient in this medicine. This medicine should be stored in a tightly closed container to avoid exposure to air or moisture. It should be kept in a dry place below 30 degrees Celsius and out of reach of children. Furthermore, transferring it to another container may cause accidents or affect quality, so caution is advised.

headache

This medicine should be stored in a tightly closed container to prevent exposure to air or moisture. It is also advisable to keep it in a dry place below 30 degrees Celsius.

Appearance

White, round film-coated tablets

Package unit

21 tablets/PTP [(7 tablets/PTP × 3)]